STOCK TITAN

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the 43rd Annual J.P.

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Butler will deliver a presentation on Thursday, January 16, 2024, at 7:30 AM PST, which will include updates on the Vafseo® (vadadustat) U.S. launch and other business matters. The conference is scheduled for January 13-16, 2025, in San Francisco. Interested parties can access the presentation webcast through the 'Investors' section of Akebia's website after the conference.

Loading...
Loading translation...
Argus Session date unavailable
-5.88% session move Open Argus
Details

News Market Reaction – AKBA

The recorded move for AKBA in the trading session of this news was -5.88%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST. Among other business updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S. launch.  

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com following the conference.

The J.P. Morgan Healthcare Conference will take place January 13-16, 2025 in San Francisco.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302334295.html

SOURCE Akebia Therapeutics, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Akebia Therapeutics (AKBA) present at the 2024 J.P. Morgan Healthcare Conference?

Akebia Therapeutics will present on Thursday, January 16, 2024, at 7:30 AM PST.

What topics will be covered in AKBA's presentation at the J.P. Morgan Healthcare Conference?

The presentation will include updates on the Vafseo® (vadadustat) U.S. launch and other business updates.

How can investors access AKBA's J.P. Morgan Healthcare Conference presentation?

Investors can access the presentation webcast through the 'Investors' section of Akebia's website at https://ir.akebia.com following the conference.

What is the focus of Akebia Therapeutics' (AKBA) business?

Akebia Therapeutics is a biopharmaceutical company focused on improving the lives of people impacted by kidney disease.

Keep reading